Here's Why Green Cross Health (NZSE:GXH) Has A Meaningful Debt Burden

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. We note that Green Cross Health Limited (NZSE:GXH) does have debt on its balance sheet. But the real question is whether this debt is making the company risky.

Advertisement

When Is Debt Dangerous?

Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. Ultimately, if the company can't fulfill its legal obligations to repay debt, shareholders could walk away with nothing. However, a more usual (but still expensive) situation is where a company must dilute shareholders at a cheap share price simply to get debt under control. Of course, debt can be an important tool in businesses, particularly capital heavy businesses. The first thing to do when considering how much debt a business uses is to look at its cash and debt together.

See our latest analysis for Green Cross Health

What Is Green Cross Health's Net Debt?

The image below, which you can click on for greater detail, shows that at March 2024 Green Cross Health had debt of NZ$34.9m, up from NZ$23.5m in one year. However, because it has a cash reserve of NZ$23.4m, its net debt is less, at about NZ$11.5m.

debt-equity-history-analysis
NZSE:GXH Debt to Equity History July 24th 2024

How Strong Is Green Cross Health's Balance Sheet?

We can see from the most recent balance sheet that Green Cross Health had liabilities of NZ$87.8m falling due within a year, and liabilities of NZ$128.9m due beyond that. On the other hand, it had cash of NZ$23.4m and NZ$26.0m worth of receivables due within a year. So its liabilities outweigh the sum of its cash and (near-term) receivables by NZ$167.3m.

Given this deficit is actually higher than the company's market capitalization of NZ$124.9m, we think shareholders really should watch Green Cross Health's debt levels, like a parent watching their child ride a bike for the first time. Hypothetically, extremely heavy dilution would be required if the company were forced to pay down its liabilities by raising capital at the current share price.

We measure a company's debt load relative to its earnings power by looking at its net debt divided by its earnings before interest, tax, depreciation, and amortization (EBITDA) and by calculating how easily its earnings before interest and tax (EBIT) cover its interest expense (interest cover). Thus we consider debt relative to earnings both with and without depreciation and amortization expenses.

While Green Cross Health's low debt to EBITDA ratio of 0.31 suggests only modest use of debt, the fact that EBIT only covered the interest expense by 3.3 times last year does give us pause. But the interest payments are certainly sufficient to have us thinking about how affordable its debt is. Unfortunately, Green Cross Health saw its EBIT slide 5.5% in the last twelve months. If that earnings trend continues then its debt load will grow heavy like the heart of a polar bear watching its sole cub. There's no doubt that we learn most about debt from the balance sheet. But it is Green Cross Health's earnings that will influence how the balance sheet holds up in the future. So if you're keen to discover more about its earnings, it might be worth checking out this graph of its long term earnings trend.

Finally, while the tax-man may adore accounting profits, lenders only accept cold hard cash. So the logical step is to look at the proportion of that EBIT that is matched by actual free cash flow. Over the last three years, Green Cross Health actually produced more free cash flow than EBIT. That sort of strong cash generation warms our hearts like a puppy in a bumblebee suit.

Our View

While Green Cross Health's level of total liabilities has us nervous. For example, its conversion of EBIT to free cash flow and net debt to EBITDA give us some confidence in its ability to manage its debt. Taking the abovementioned factors together we do think Green Cross Health's debt poses some risks to the business. So while that leverage does boost returns on equity, we wouldn't really want to see it increase from here. The balance sheet is clearly the area to focus on when you are analysing debt. However, not all investment risk resides within the balance sheet - far from it. These risks can be hard to spot. Every company has them, and we've spotted 3 warning signs for Green Cross Health (of which 1 can't be ignored!) you should know about.

Of course, if you're the type of investor who prefers buying stocks without the burden of debt, then don't hesitate to discover our exclusive list of net cash growth stocks, today.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NZSE:GXH

Green Cross Health

Provides health care and advice services to communities in New Zealand.

Good value with proven track record.

Advertisement

Weekly Picks

LO
Lou_Basenese
GIFT logo
Lou_Basenese on Giftify ·

Giftify ($GIFT): A Small-Cap Incentives Platform with More ScaleThan Its Valuation Suggests

Fair Value:US$2.551.6% undervalued
19 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
TR
tripledub
META logo
tripledub on Meta Platforms ·

The $135 Billion Bet That Should Make Every Shareholder Nervous

Fair Value:US$58016.4% overvalued
29 users have followed this narrative
3 users have commented on this narrative
30 users have liked this narrative
TH
LMT logo
TheBestInvestor on Lockheed Martin ·

Orbit + Aero + Defense

Fair Value:US$673.8823.8% undervalued
17 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative
AG
Agricola
STGO logo
Agricola on Steppe Gold ·

A case for Steppe Gold, bear case CAD $4, base case CAD $15, bull case CAD $25

Fair Value:CA$2594.4% undervalued
22 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative

Updated Narratives

RO
RockeTeller
LG logo
RockeTeller on Lahontan Gold ·

15,000% Nevada's Gold Miner Play

Fair Value:CA$22.9898.2% undervalued
15 users have followed this narrative
7 users have commented on this narrative
1 users have liked this narrative
SO
NEE logo
sorkdhkddlek on NextEra Energy ·

NEE Valuation — The Convergence of Grid Stability and AI Growth

Fair Value:US$94.331.0% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
PE
Peptide_gcr
BANB logo
Peptide_gcr on Bachem Holding ·

Bachem Holding - The Purest Public Peptide Play?

Fair Value:CHF 249.9972.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TR
tripledub
MSFT logo
tripledub on Microsoft ·

Everyone's Terrified Microsoft Will Keep Spending. I'm Terrified They'll Stop.

Fair Value:US$3957.5% overvalued
52 users have followed this narrative
3 users have commented on this narrative
43 users have liked this narrative
KI
NVDA logo
Kingman1152 on NVIDIA ·

NVIDIA will see a profit margin surge of 55% in the next 5 years

Fair Value:US$305.231.8% undervalued
67 users have followed this narrative
2 users have commented on this narrative
23 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$579.5726.7% undervalued
1391 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative